Loading clinical trials...
Loading clinical trials...
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Conditions
Interventions
placebo plus docetaxel
BIBF 1120 plus docetaxel
Locations
210
Austria
LKH-Univ. Hospital Graz
Graz, Austria
KH St. Vinzenz, Zams, Int. Abtlg.
Kufstein, Austria
AKH d. Stadt Linz, Pulmologie
Linz, Austria
Bobruisk Inter-distict
Babruysk, Belarus
Brest Regional Clinical
Brest Region, Belarus
Gomel Regional Clinical
Homyel, Belarus
Start Date
December 3, 2008
Primary Completion Date
November 2, 2010
Completion Date
November 13, 2017
Last Updated
December 5, 2018
NCT06667908
NCT04165798
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions